AbbVie Report Results of Rinvoq (upadacitinib) in Second P-III Induction Study for Ulcerative Colitis
Shots:
- The P-III U-ACCOMPLISH induction study involves assessing upadacitinib (45 mg- qd) vs PBO in patients with mod. to sev. UC
- The study met its 1EPs @8wks. i.e- patients achieved clinical remission (per Adapted Mayo Score) (31% vs 4%); met its 2EPs i.e clinical response @8wks. & @2wks. (74% vs 25% & 63% vs 26%); endoscopic improvement (44% vs 8%); histologic endoscopic mucosal improvement (37% vs 6%)
- The safety results were consistent with the previous P-III induction study- with no new safety risks observed. Rinvoq is a selective and reversible JAK inhibitor- being studied as an oral therapy for mod. to sev. UC and several other immune-mediated diseases
Ref: Abbvie | Image: abbvie
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com